$36.48+0.02 (+0.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Pacira BioSciences (PCRX) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Sep 30, 2026*: more funds added or entered than trimmed or exited, mild accumulation (33 new · 94 increased · 86 reduced · 25 closed · 21 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 50 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 259 filers, Sep 30, 2026
# 13F FUNDS
259
13F VALUE
$1.2B
45.9M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Cross Shawn | Chief Financial Officer | Disposed · Tax withholding | 9,540 | $36.39 | ↗ |
| Oct 8, 2026 | Riker Lauren Bullaro | Senior Vice President, Finance | Acquired · Option exercise | 6,000 | $32.35 | ↗ |
| Oct 8, 2026 | Riker Lauren Bullaro | Senior Vice President, Finance | Disposed · Open-market sale | 6,000 | $36.32 | ↗ |
| Oct 8, 2026 | Riker Lauren Bullaro | Senior Vice President, Finance | Disposed · Option exercise | 6,000Stock Option (Right to Buy) | — | ↗ |
| Aug 17, 2026 | SLONIN JONATHAN | Chief Medical Officer | Disposed · Open-market sale | 3,040 | $23.23 | ↗ |
| Jun 11, 2026 | Riker Lauren Bullaro | Senior Vice President, Finance | Disposed · Open-market sale | 6,115 | $23.50 | ↗ |
| Jun 10, 2026 | Hirawat Samit | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | Hirawat Samit | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | CHRISTIE CHRISTOPHER | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | CHRISTIE CHRISTOPHER | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | WIGGANS THOMAS G | director | Acquired · Grant / award | 32,675Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | Young Alethia | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | Young Alethia | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | YANG MICHAEL J. | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | YANG MICHAEL J. | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | BIGAL MARCELO | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | BIGAL MARCELO | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | Froimson Mark | director | Acquired · Grant / award | 6,405 | — | ↗ |
| Jun 10, 2026 | Froimson Mark | director | Acquired · Grant / award | 10,891Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | Brege Laura | director | Acquired · Grant / award | 6,405 | — | ↗ |
* Holdings as reported for Sep 30, 2026, 50 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Pacira BioSciences?
Pacira BioSciences was held by 259 13F filers as of Sep 30, 2026.
Not investment advice.

